Novel cyclooxygenase-catalyzed bioactive prostaglandin F2alpha from physiology to new principles in inflammation.
Prostaglandin F2alpha (PGF2alpha), a foremost stable vasoactive cyclooxygenase (COX)-catalyzed prostaglandin, regulates a number of key physiological functions such as luteolysis, ovarian function, luteal maintenance of pregnancy, and parturition as a constitutive part of ongoing reproductive processes of the body. It has recently been implicated in the regulation of intricate pathophysiological processes, such as acute and chronic inflammation, cardiovascular and rheumatic diseases. Since the discovery of a second isoform of COXs, it has been shown that PGF2alpha can be formed in vivo from arachidonic acid through both isoforms of COXs, namely cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Being synthesized in various parts of the body, it metabolizes instantly to a number of rather inactive metabolites mainly in the lungs, liver, kidney, and efficiently excretes into the urine. 15-Keto-dihydro-PGF2alpha, a major stable metabolite of PGF2alpha that reflects in vivo PGF2alpha biosynthesis, is found in larger quantities than its parent compound in the circulation and urine in basal physiological conditions, with short-lived pulses during luteolysis, induced termination of pregnancy and parturition, and is increased in tissues and various body fluids during acute, sub-chronic, and severe chronic inflammation. Further, the close relationship of PGF2alpha with a number of risk factors for atherosclerosis indicates its major role in inflammation pathology. This review addresses multiple aspects of PGF2alpha in addition to its emerging role in physiology to inflammation.
Basu
Samar
S
Clinical Nutrition and Metabolism, Department of Public Health and Caring Sciences, Faculty of Medicine, Uppsala University, Uppsala Science Park, Uppsala, Sweden. samar.basu@pubcare.uu.se
D000818:Animals; D050197:Atherosclerosis / Q000209:etiology; D001826:Body Fluids / Q000737:chemistry; D002252:Carbon Tetrachloride Poisoning / Q000503:physiopathology; D002339:Carotid Arteries / Q000473:pathology; D051545:Cyclooxygenase 1 / Q000378:metabolism*; D051546:Cyclooxygenase 2 / Q000378:metabolism*; D048909:Diabetes Complications / Q000503:physiopathology; D015237:Dinoprost / Q000031:analogs & derivatives / Q000096:biosynthesis / Q000378:metabolism / Q000502:physiology*; D005260:Female; D006801:Humans; D007249:Inflammation / Q000503:physiopathology*; D044243:Linoleic Acids, Conjugated / Q000494:pharmacology; D003341:Luteolysis / Q000187:drug effects; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology; D009765:Obesity / Q000150:complications; D011247:Pregnancy; D012307:Risk Factors; D012772:Shock, Septic / Q000503:physiopathology; D012907:Smoking / Q000009:adverse effects
D044243:Linoleic Acids, Conjugated; C008228:15-keto-13,14-dihydroprostaglandin F2alpha; D015237:Dinoprost; D051545:Cyclooxygenase 1; D051546:Cyclooxygenase 2